Litcius/Paper detail

Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Toby M. Maher, J. Goldin, John Hood, Jim Pitman, Martín de los Rios, Brian P. Hobbs, Andrea Ban Yu-Lin, Ivette Buendía-Roldán, Francis Thien, Jae W. Song, Pablo Perea, Alicia Ramírez‐Rivera, A. DiFrancesco

2025The Lancet Respiratory Medicine7 citationsDOI

Topics & Concepts

MedicineIdiopathic pulmonary fibrosisInternal medicineGastroenterologyClinical trialMEDLINEPulmonary fibrosisFibrosisPhases of clinical researchPathologyRespiratory diseaseSurgeryInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisHedgehog Signaling Pathway StudiesLung Cancer Treatments and Mutations
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial | Litcius